SCHEMBL1999820

SCHEMBL1999820

CCOC(=O)c1cc(N)c(=O)n(CC)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
NPC1 O15118 1/20 0.42
MAPT P10636 1/20 0.42
RAB9A P51151 1/20 0.42
RECQL P46063 1/20 0.42
PDE4A P27815 7/20 0.42
PDE4B Q07343 7/20 0.42
PDE4C Q08493 7/20 0.42
PDE4D Q08499 7/20 0.42
HSD17B10 Q99714 3/20 0.42
GAA P10253 2/20 0.42
KDM4E B2RXH2 2/20 0.42
HPGD P15428 2/20 0.42
FAAH O00519 2/20 0.42
CYP1A2 P05177 1/20 0.41
POLB P06746 1/20 0.41
MAPK1 P28482 1/20 0.41
ADORA3 P0DMS8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1738098 0.83 KMT2A (0.45) ALDH1A1KMT2AMEN1NPC1MAPT
SCHEMBL2001144 0.83 MAPT (0.45) ALDH1A1KMT2AMEN1MAPTRECQL
SCHEMBL1999700 0.83 ADORA3 (0.39) ALDH1A1NPC1MAPTRAB9ARECQL
SCHEMBL1998314 0.82 SMN1; SMN2 (0.44) ALDH1A1KMT2AMEN1MAPTKDM4E
SCHEMBL1996418 0.81 MARS1 (0.42) ALDH1A1NPC1MAPTRECQLGAA
SCHEMBL1994640 0.81 KDM4E (0.43) ALDH1A1KMT2AMEN1NPC1MAPT
SCHEMBL1996427 0.80 MMP9 (0.43) ALDH1A1KMT2AMAPTKDM4EFAAH
SCHEMBL1234127 0.80 AURKA (0.52) ALDH1A1KMT2AMEN1NPC1MAPT
SCHEMBL1994564 0.79 CNR2 (0.42) ALDH1A1NPC1MAPTRAB9AHSD17B10
SCHEMBL1999165 0.79 GABRP (0.38) ALDH1A1KMT2AMEN1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960383-B2 phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease LABORATORIOS ALMIRALL SA (ES) 2011-06-14 US disclosed
EP-1758869-B1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS ALMIRALL SA (ES) 2010-12-22 EP disclosed
US-20080280918-A1 Pyridazin-3(2H)-One Derivatives and Their Use as Pde4 Inhibitors ALMIRALL PRODESFARMA, SA (ES) 2008-11-13 US disclosed
EP-1758869-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS Almirall Prodesfarma, S.A. (ES) 2007-03-07 EP disclosed
WO-2005123692-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS LABORATORIOS ALMIRALL, S.A. (ES) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280918-A1 Pyridazin-3(2H)-One Derivatives and Their Use as Pde4 Inhibitors PDE12, PDE4A, PDE4B ALDH1A1 457/4885KMT2A 2498/4885MEN1 4629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.